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The carboxylic acid–primary amide supramolecular hetero-
synthon is exploited for the generation of pharmaceutical
co-crystals that contain two active pharmaceutical ingredients
that are polymorphic in their pure forms.
That crystal engineering has matured into a form of supramole-
cular synthesis is the consequence of several decades of research
focused upon gaining a better understanding of the forces that
sustain and direct crystal structures.1 The fundamental precept of
crystal engineering is that crystals are in effect ‘‘supermolecules’’,2
the result of a series of directional, and therefore predictable,
molecular recognition events or supramolecular synthons.3 A
salient feature of crystal engineered structures is that they are
designed from first principles and can therefore consist of a diverse
range of chemical components as exemplified by coordination
polymers (i.e., metals and organic ligands),4 polymers sustained
by organometallic linkages5 and hydrogen bonded organic
networks.1d,e,6 Active pharmaceutical ingredients, APIs, are
extremely valuable materials so it is perhaps surprising that crystal
engineering has only recently addressed APIs via development of a
fourth class of API, pharmaceutical co-crystals.7 Whereas co-
crystals have long been known as addition compounds8 or organic
molecular compounds9 the Cambridge Structural Database, CSD,10
indicates that they remain relatively unexplored with very few
entries prior to 1960 and even now there are only ca. 1450 hydro-
gen bonded co-crystals vs. almost 35,000 hydrates. The potential
benefits of co-crystals include the generation of novel NLO
materials,11 solvent-free organic synthesis,12 modification of
photographic films13 and formulation of APIs,7,14 which is the
focus of this contribution.
Pharmaceutical co-crystals, i.e., co-crystals that are formed
between an API and a co-crystal former that is a solid under
ambient conditions, represent a new paradigm in API formulation
that might address important intellectual and physical property
issues in the context of drug development and delivery. In this
contribution we demonstrate how the carboxylic acid–primary
amide supramolecular heterosynthon7c can be exploited to generate
pharmaceutical co-crystals of a polymorphic API, piracetam, 1,15
in which the co-crystal formers are also polymorphic and APIs in
their own right: gentisic acid, 2,16 and p-hydroxybenzoic acid, 3.17
Piracetam, (2-oxo-1-pyrrolidinyl)acetamide, 1, is a nootropic
drug that works to boost intelligence by stimulating the central
nervous system.18 Four polymorphic forms of 1 have been
reported15 although only three, refcode BISMEV, have been
deposited in the CSD. No co-crystals, solvates or hydrates have
been reported although one study suggests that 1 may exhibit as
many as 6 polymorphs.19 Gentisic acid, 2,5-dihydroxybenzoic acid,
2, is an aspirin metabolite that exhibits NSAID activity.20 Gentisic
acid exhibits two polymorphic forms21 and forms co-crystals with
piperazine-2,5-dione and L-proline.22 Single crystals of the 1:1
co-crystal of piracetam and gentisic acid, 4, were obtained via slow
evaporation from acetonitrile. Co-crystal 4 can also be prepared
via grinding or slurrying in water. Co-crystal 4 was characterized
by IR, melting point, DSC, PXRD and single crystal X-ray
diffraction.23 The carboxylic acid–amide supramolecular hetero-
synthon has been long documented24 and 71 of the 153 structures
in the CSD that contain both a carboxylic acid and a primary
amide are sustained by this interaction. It would therefore be
unsurprising if the acid–amide supramolecular heterosynthon
were to occur in 4 and, as revealed by Fig. 1a, this is indeed the
case. The remaining H-bond donors are satisfied as follows:
the 2-hydroxy group of gentisic acid forms an intramolecular
hydrogen bond and acts an acceptor to the anti-oriented NH of
the primary amide; the 5-hydroxy group of gentisic acid serves as a
hydrogen bond donor to the ring carbonyl of piracetam (Fig. 1b).
The resulting network exhibits 4,4-topology and it is 2-fold
interpenetrated (Fig. 1c).
Piracetam also forms a 1:1 co-crystal with p-hydroxybenzoic
acid, 5. Co-crystal 5 can be crystallized from acetonitrile via slow
evaporation. Co-crystal 5 can also be prepared via grinding or
slurrying in water. The crystal structure of 525 reveals the presence
of the acid–amide supramolecular heterosynthon which in turn
dimerizes to form a tetrameric motif sustained by N–H…O
hydrogen bonding (Fig. 2). This tetrameric motif is found in 10
(14%) of the 71 structures in the CSD that contain acid–amide
supramolecular heterosynthons.26 The ring carbonyl of piracetam
molecules and the hydroxy group of 3 H-bond each tetramer to
four others, thereby affording a 3-fold interpenetrated network.
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That APIs are promiscuous in the context of polymorphism is a
critical issue for the pharmaceutical industry:27 from a regulatory
perspective it has been established that bioactivity can change
between forms; from an intellectual property perspective, poly-
morphic forms are established in law as discrete materials and new
forms can be patented. We have therefore investigated the general
occurrence of polymorphism in existing co-crystals. A CSD search
revealed only eleven examples of polymorphism in hydrogen
bonded co-crystals for which coordinates are available for two or
more forms.28 Interestingly, the polymorphism in these eleven co-
crystals can be attributed to conformational flexibility or different
packing between layers, i.e., the hydrogen bonded supramolecular
synthons are consistent. Co-crystals 4 and 5 were therefore screened
for the existence of polymorphs using solvent-drop grinding, a
technique that has been shown to be able to generate and control
polymorphism.29 Mechanical grinding experiments were con-
ducted in reaction vessels by adding gentisic acid or p-hydroxy-
benzoic acid to solid piracetam form A. A group of 23 solvents
(water, acetone, methanol, ethanol, ethyl acetate, n-hexane, toluene,
acetonitrile, tetrahydrofuran, isopropyl acetate, benzyl alcohol,
nitromethane, dimethyl amine, 2-butanol, ethyl formate, acetic
acid, methyl ethyl ketone, methyl tert-butyl ether, chlorobenzene,
N-methyl pyrrolidone, 1,2-dichloroethane, dimethyl sulfoxide and
dimethoxyethane) was evaluated by adding a different solvent to
each well. The samples were ground for 20 minutes and charac-
terized using powder X-ray diffraction. Co-crystals 4 and 5 were
also obtained by slurrying 0.62 mmol of piracetam and 0.62 mmol
of gentisic acid or p-hydroxybenzoic acid in water (100mL) for 60
or 16 hours, respectively. Co-crystals 4 or 5 were obtained from all
grinding and slurrying reactions as a mixture with one or both of
the starting materials, i.e., co-crystals 4 and 5 do not exhibit poly-
morphism based on a series of solvent-mediated grinding experi-
ments (See ESI for experimental details and PXRD spectra{).
In summary, we address herein the use of supramolecular
heterosynthons, in particular the carboxylic acid–primary amide
Fig. 1 (a) The carboxylic acid–amide supramolecular heterosynthon in
the 1:1 co-crystal of piracetam and gentisic acid, 4. Structural parameters:
O–Hacid…O 5 2.590(15) A˚, N–Hsyn…O 5 2.907(18) A˚, N–Hanti…O 5
2.944(19) A˚. (b) A portion of the hydrogen bond network in 4. (c) A space-
filling model of the 2-fold interpenetration that occurs in 4.
Fig. 2 (a) The carboxylic acid–amide supramolecular heterosynthon in
the tetrameric motif that sustains 5. Structural parameters: O–Hacid…O5
2.598(3)A˚, N–Hsyn…O 5 2.955(3) A˚, N–Hanti…O 5 2.908(3) A˚. (b) A
portion of the hydrogen bond network in 5.
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dimer, to crystal engineer pharmaceutical co-crystals from pairs of
APIs that are polymorphic in their pure forms. An analysis of the
CSD and evaluation of new pharmaceutical co-crystals suggests
that these co-crystals are robust enough to be prepared via
solution, slurry or solid-state methods and that they appear to be
less prone to polymorphism than the corresponding single
component APIs. However, it should be stressed that the amount
of data available concerning the extent of polymorphism in
co-crystals remains minimal and that one will not be able to make
definitive conclusions even if exhaustive high throughput screen-
ings are conducted.
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